Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1987 1
1994 1
2000 1
2009 1
2013 1
2014 2
2023 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Guideline for allergological diagnosis of drug hypersensitivity reactions: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) in cooperation with the German Dermatological Society (DDG), the Association of German Allergologists (ÄDA), the German Society for Pediatric Allergology (GPA), the German Contact Dermatitis Research Group (DKG), the German Society for Pneumology (DGP), the German Society of Otorhinolaryngology, Head and Neck Surgery, the Austrian Society of Allergology and Immunology (ÖGAI), the Austrian Society of Dermatology and Venereology (ÖGDV), the German Academy of Allergology and Environmental Medicine (DAAU), and the German Documentation Center for Severe Skin Reactions (dZh).
Brockow K, Wurpts G, Trautmann A, Pfützner W, Treudler R, Bircher AJ, Brehler R, Buhl T, Dickel H, Fuchs T, Jakob T, Kurz J, Kreft B, Lange L, Merk HF, Mockenhaupt M, Mülleneisen N, Ott H, Ring J, Ruëff F, Sachs B, Sitter H, Wedi B, Wöhrl S, Worm M, Zuberbier T. Brockow K, et al. Allergol Select. 2023 Aug 9;7:122-139. doi: 10.5414/ALX02422E. eCollection 2023. Allergol Select. 2023. PMID: 37705676 Free PMC article.
Survey of aspirin administration in systemic mastocytosis.
Butterfield JH. Butterfield JH. Prostaglandins Other Lipid Mediat. 2009 Apr;88(3-4):122-4. doi: 10.1016/j.prostaglandins.2009.01.001. Epub 2009 Jan 22. Prostaglandins Other Lipid Mediat. 2009. PMID: 19429499
BACKGROUND: Previous recommended doses for aspirin use in systemic mastocytosis have been 3.9-5.2g/d. Here, the aspirin doses and biochemical responses of patients with systemic mastocytosis given aspirin to decrease prostaglandin D(2) levels an …
BACKGROUND: Previous recommended doses for aspirin use in systemic mastocytosis have been 3.9-5.2g/d. Here, the aspirin …
Treatment of systemic mast cell disorders.
Worobec AS. Worobec AS. Hematol Oncol Clin North Am. 2000 Jun;14(3):659-87, vii. doi: 10.1016/s0889-8588(05)70301-4. Hematol Oncol Clin North Am. 2000. PMID: 10909045 Review.
The heterogeneous nature of disease manifestations in mastocytosis requires the individualization of therapy to each patient's clinical presentation and prognosis. The mainstay of treatment for most categories of mastocytosis are H1 and H2 antihistamines with the ad …
The heterogeneous nature of disease manifestations in mastocytosis requires the individualization of therapy to each patient's clinic …
Presentation of untreated systemic mastocytosis as recurrent, pulseless-electrical-activity cardiac arrests resistant to cardiac pacemaker.
Butterfield JH, Weiler CR. Butterfield JH, et al. Int Arch Allergy Immunol. 2014;163(2):130-4. doi: 10.1159/000356487. Epub 2013 Dec 4. Int Arch Allergy Immunol. 2014. PMID: 24335343
Treatment with a combination of H1 and H2 receptor blockers reduced flushing and eliminated hypotension. Maintenance medication included aspirin, cetirizine, ranitidine, montelukast, oral cromolyn sodium and an epinephrine autoinjector (as needed). At 6-month follow …
Treatment with a combination of H1 and H2 receptor blockers reduced flushing and eliminated hypotension. Maintenance medication inclu …
Shock syndrome associated with mastocytosis: pharmacologic reversal of the acute episode and therapeutic prevention of recurrent attacks.
Roberts LJ 2nd, Turk JW, Oates JA. Roberts LJ 2nd, et al. Adv Shock Res. 1982;8:145-52. Adv Shock Res. 1982. PMID: 7136941
Patients with mastocytosis at times experience spontaneous episodes of severe flushing and vasodilatory shock. ...We have now generalized our initial findings and have found an increased production of prostaglandin D2 ranging from 1.5-to 32.6-fold in eight additiona …
Patients with mastocytosis at times experience spontaneous episodes of severe flushing and vasodilatory shock. ...We have now …
Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.
Ravi A, Butterfield J, Weiler CR. Ravi A, et al. J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):775-8. doi: 10.1016/j.jaip.2014.06.011. Epub 2014 Nov 6. J Allergy Clin Immunol Pract. 2014. PMID: 25439370
RESULTS: Urinary 11beta-PGF2alpha was the most frequently elevated product in MCAS of our 25-patient cohort. Flushing and pruritus had the greatest correlation with elevation of 24-hour urine 11beta-PGF2alpha value at baseline. ...Eight of 9 patients with MCAS and with ele …
RESULTS: Urinary 11beta-PGF2alpha was the most frequently elevated product in MCAS of our 25-patient cohort. Flushing and pruritus ha …
Increased plasma calcitonin levels in systemic mast cell disease.
Yocum MW, Butterfield JH, Gharib H. Yocum MW, et al. Mayo Clin Proc. 1994 Oct;69(10):987-90. doi: 10.1016/s0025-6196(12)61825-4. Mayo Clin Proc. 1994. PMID: 7934197
Aspirin therapy for patients with systemic mast cell disease (SMCD) decreases the production of prostaglandin D2, which is thought to be a major mediator of flushing. Paradoxically, in 5 to 10% of patients with SMCD, administration of aspirin causes massive m …
Aspirin therapy for patients with systemic mast cell disease (SMCD) decreases the production of prostaglandin D2, which is thought to …
Systemic mastocytosis: management of an unusual case with histamine (H1 and H2) antagonists and cyclooxygenase inhibition.
Crawhall JC, Wilkinson RD. Crawhall JC, et al. Clin Invest Med. 1987 Jan;10(1):1-4. Clin Invest Med. 1987. PMID: 2880686
Based upon the experience of others with the management of patients with systemic mastocytosis who showed exceptional reaction to cyclooxygenase inhibition, it was decided to treat him with H1 and H2 blockade followed by aspirin, another cyclooxygenase inhibitor. Th …
Based upon the experience of others with the management of patients with systemic mastocytosis who showed exceptional reaction to cyc …